Heteroaryl compounds as BTK inhibitors and uses thereof

US10329270B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Hui Qiu · Lexington, US
• Richard D. Caldwell · Melrose, US
• Constantin Neagu · Belmont, US
• Igor Mochalkin · Westford, US
• Lesley Liu-Bujalski · Bedford, US
• Reinaldo Jones · Lowell, US
• Devon Tate · Bedford, US
• Theresa L. Johnson · Salem, US
• Anna Gardberg · Arlington, US

Key dates

• Filing date: Oct 21, 2014
• Grant date: Jun 25, 2019
• Expiry date: Oct 21, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F5/022
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.